SCHEMBL15907199

SCHEMBL15907199

C#Cc1cccc(NC(=O)c2cccc(C(C)=O)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.60
EGFR P00533 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
KMT2A Q03164 9/20 0.57
POLB P06746 2/20 0.57
MEN1 O00255 7/20 0.56
RXFP1 Q9HBX9 2/20 0.56
NPC1 O15118 5/20 0.56
RAB9A P51151 5/20 0.56
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907176 0.94 KMT2A (0.61) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL3838614 0.91 HDAC1 (0.66) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL22627078 0.89 MEN1 (0.61) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL13023381 0.88 HDAC1 (0.64) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL17818408 0.87 KCNK3 (0.72) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL5612900 0.86 KCNK3 (0.69) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL15907214 0.85 KMT2A (0.50) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL13132962 0.85 HDAC3 (0.60) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL16236279 0.84 NPC1 (0.67) HDAC3EGFRHDAC4HDAC1HDAC7
SCHEMBL16236545 0.84 KMT2A (0.67) HDAC3EGFRHDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 HDAC3 3411/4885EGFR 334/4885HDAC4 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.